Cancer Treatment Today

Nexavar is an orally active, multi-kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma. Nexavar has wide anti-tumor effects and has been tested in a variety of other cancers, including prostate and melanoma.In a pilot study, 6 patients with recurrent NSCLC were treated with single agent Nexavar®. This study demonstrated single agent activity with partial responses in two patients

SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Thiis condtion occurrs with lung cancer and less commonly other cancer or in associaitons with certain chemotherapy